11/20
11:16 am
cing
Cingulate Inc. (NASDAQ: CING) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Medium
Report
Cingulate Inc. (NASDAQ: CING) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
11/7
07:30 am
cing
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Low
Report
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
10/8
03:15 pm
cing
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
Medium
Report
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
9/12
08:30 am
cing
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
Medium
Report
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
8/27
04:30 pm
cing
Cingulate to Participate in Benzinga All Live Access Event
High
Report
Cingulate to Participate in Benzinga All Live Access Event
8/23
04:45 pm
cing
Cingulate Announces Adjournment of Special Meeting
Medium
Report
Cingulate Announces Adjournment of Special Meeting